Fractalkine-CX3CR1 Axis in Periodontal Therapy

December 13, 2025 updated by: Zeynep Pınar Yucel, Giresun University

Fractalkine and CX3CR1 Dynamics in Gingivitis and Periodontitis Before and After Therapy

This study aimed to evaluate gingival crevicular fluid (GCF) levels of fractalkine/CX3CL1 and CX3CR1 in patients with gingivitis and periodontitis before and after non-surgical periodontal therapy.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Thirty stage 3 periodontitis, thirty gingivitis and thirty periodontally healthy individuals were enrolled in the study. Clinical periodontal measurements were recorded; gingivitis and periodontitis patients underwent non-surgical periodontal treatment, and GCF samples were collected at baseline and at 1 and 3 months after treatment. CX3CL1 and CX3CR1 were determined by ELISA.

Study Type

Interventional

Enrollment (Actual)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Turkey
      • Giresun, Turkey, Turkey (Türkiye), 28100
        • Giresun University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. 25-50 years of age
  2. having at least 20 natural teeth, excluding third molars
  3. having no systemic disease
  4. non-smokers
  5. criteria for healthy control group: BOP < 10% and PD ≤ 3 mm without clinical attachment loss or radiographic sign of alveolar bone destruction
  6. criteria for stage 3 periodontitis group: interdental CAL ≥ 5 mm at least 2 non-adjacent teeth, PD ≥ 6 mm and radiographic bone loss extending to the mid-third of the root or beyond.

Exclusion Criteria:

  1. having any systemic diseases,
  2. smoking
  3. current pregnancy or lactation
  4. a history of periodontal treatment in the past 6 months
  5. using antibiotic, anti-inflammatory drugs or any other drugs within the past 6 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: stage 3 periodontitis
GCF samples were collected at baseline and at 1 and 3 months after treatment from periodontitis patients.
Other: Non-surgical periodontal treatment
Scaling and root planing, oral hygiene education and motivation.
Active Comparator: Gingivitis
GCF samples were collected at baseline and at 1 and 3 months after treatment from gingivitis patients.
Other: Non-surgical periodontal treatment
Scaling and root planing, oral hygiene education and motivation.
No Intervention: Periodontally healthy controls
GCF samples were collected from periodontally healthy controls at baseline for once.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in the levels of biochemical parameters
Time Frame: Baseline and 1 and 3 months after treatment
The levels of Fractalkine and CX3CR1 before and after periodontal treatment in gingivitis and periodontitis patients.
Baseline and 1 and 3 months after treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Giresun University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 15, 2022

Primary Completion (Actual)

November 15, 2023

Study Completion (Actual)

December 10, 2023

Study Registration Dates

First Submitted

December 13, 2025

First Submitted That Met QC Criteria

December 13, 2025

First Posted (Actual)

December 29, 2025

Study Record Updates

Last Update Posted (Actual)

December 29, 2025

Last Update Submitted That Met QC Criteria

December 13, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • OMU KAEK 2022/85
  • SAĞ-BAP-A-240222-47 (Other Grant/Funding Number: Giresun University Scientific Research Projects Coordination Unit)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Periodontitis

Clinical Trials on Non-surgical periodontal treatment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe